Clinical Trial Update: Vasodilators and Anti-Oxidant Therapy in Early ATN [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating vasodilators and antioxidant therapy for early acute kidney injury was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Snippet

Sponsor: Southeast Renal Research Institute | Conditions: Acute Renal Failure | Phase 2, Phase 3 | Status: WITHDRAWN